Valuation: Voyageur Pharmaceuticals Ltd.

Market Cap 31.69M 22.49M 19.78M 18.37M 16.9M 2.18B 32.26M 220M 85.69M 1.06B 84.42M 82.59M 3.68B P/E 2024
-5.24x
P/E 2025 -7.5x
Enterprise Value 31.46M 22.32M 19.63M 18.24M 16.77M 2.16B 32.02M 218M 85.07M 1.05B 83.8M 81.99M 3.66B EV / Sales 2024
-
EV / Sales 2025 2,423,581,172x
Free-Float
93.07%
Yield 2024 *
-
Yield 2025 -
1 day-9.09%
Current month+5.26%
3 months+25.00%
Current year-23.14%
1 week 0.1
Extreme 0.1
0.11
1 month 0.09
Extreme 0.0874
0.11
Current year 0.01
Extreme 0.014
0.2
1 year 0
Extreme 0.0033
0.2
3 years 0
Extreme 0.0005
0.25
5 years 0
Extreme 0.0005
0.25
10 years 0
Extreme 0.0005
0.25
Manager TitleAgeSince
Chief Executive Officer - 2019-06-30
Director of Finance/CFO - 2022-08-16
Chief Tech/Sci/R&D Officer - 2024-09-16
Director TitleAgeSince
Director/Board Member - 2017-12-05
Director/Board Member - 2019-06-30
Chairman - 2025-04-29
Change 5-day change 1-year change 3-year change Capi.($)
-9.09%0.00% - - 22.49M
+1.97%+1.43%+48.44%+156.66% 1,057B
+1.42%+3.72%+53.32%+52.34% 624B
+1.43%+0.99%+34.83%+78.74% 454B
+0.64%+5.06%+32.44%+28.37% 341B
-0.61%+1.57%+35.74%+39.82% 297B
-0.47%+0.22%+15.73%+17.09% 262B
-0.71%-3.41%-28.72%-42.06% 215B
+1.49%-0.02%+20.14%+58.21% 201B
+0.40%-3.99%+15.23%+62.28% 162B
Average -0.35%+0.77%+25.24%+50.16% 401.55B
Weighted average by Cap. +1.04%+1.57%+34.99%+75.48%

Financials

2024 2025
Net sales - 0.01 0.01 0.01 0.01 0.01 0.8 0.01 0.08 0.03 0.39 0.03 0.03 1.36
Net income -1.71M -1.21M -1.07M -990K -910K -117M -1.74M -11.84M -4.62M -57.22M -4.55M -4.45M -199M -3.53M -2.51M -2.2M -2.05M -1.88M -243M -3.6M -24.49M -9.55M -118M -9.41M -9.21M -411M
Net Debt -113K -79.92K -70.29K -65.3K -60.06K -7.74M -115K -781K -305K -3.78M -300K -294K -13.1M -231K -164K -144K -134K -123K -15.84M -235K -1.6M -623K -7.73M -614K -601K -26.81M
Logo Voyageur Pharmaceuticals Ltd.
Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine active pharmaceutical ingredients (API) and imaging contrast agents for medical radiology. It focuses on vertically integrating the barium and iodine contrast markets. In addition, Voyageur is pursuing the development of new endo fullerene drugs. Its products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. At the core of its operations, the Company also owns a 100% interest in the Frances Creek Project, which boasts a mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.
Employees
-
Date Price Change Volume
26-07-22 US$0.1000 -9.09% 47,000
26-07-21 US$0.1100 +10.00% 39,000
26-07-20 US$0.1000 0.00% 14,000
26-07-17 US$0.1000 0.00% 6,000

Annual profits - Rate of surprise